Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials.

Abstract:

BACKGROUND:Data on the comparative efficacy of fulvestrant and other endocrine treatments are inconsistent. Clinical markers predictive of greater benefit from fulvestrant compared to the alternate endocrine agents have not been identified. METHODS:We searched the literature from inception to May 2015, using MEDLINE, EMBASE, and major conference proceedings. We included randomized controlled trials (RCTs) that compared fulvestrant containing arm to either tamoxifen or an aromatase inhibitors (AI) and presented results for subgroup analyses as Hazard Ratios (HR) for Time to Progression (TTP) or Progression Free Survival (PFS). Subgroup analyses reported in at least two RCTs were included. Data were then weighted using generic inverse variance approach and pooled in meta-analysis using RevMan 5.3 software. Difference between sub-groups was tested with chi(2) statistics. RESULTS:Analysis included 4 RCTs comparing fulvestrant-based therapy to AI alone and comprising 2382 patients (1190 on fulvestrant and 1192 on control arms). TTP/PFS was the primary endpoint in all included studies. Four sub-groups fulfilled our criteria. Fulvestrant was associated with greater benefit in patients with visceral metastasis (HR 0.85 vs 1.02 for no visceral disease, p for difference=0.05) and in those patients with a time to recurrence >5 years (HR 0.80 vs 1.09 for recurrence ⩽5 years, p for difference=0.02). There was no apparent difference in benefit based on age >65 years (HR 0.86 vs 0.96, p for difference=0.32) or HER2/neu status (HR 0.36 vs 0.92, p for difference=0.09). CONCLUSION:Patients with advanced breast cancer with visceral involvement and longer time from diagnosis to recurrence had significantly better TTP/PFS with the use of fulvestrant. These results may have implications for selection of patients in the design of future clinical trials and to inform treatment decisions in clinical practice.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Graham J,Pitz M,Gordon V,Grenier D,Amir E,Niraula S

doi

10.1016/j.ctrv.2016.02.004

subject

Has Abstract

pub_date

2016-04-01 00:00:00

pages

1-6

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(16)00019-0

journal_volume

45

pub_type

杂志文章,meta分析,评审
  • Electrochemotherapy of chest wall breast cancer recurrence.

    abstract::Chest wall breast cancer recurrence after mastectomy is a disease difficult to treat. Its incidence varies between 5% and 30% in different subset of patients. When possible, radical surgical therapy represents the main treatment approach, however when the disease progresses and/or treatments are not successful, ulcera...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.07.006

    authors: Sersa G,Cufer T,Paulin SM,Cemazar M,Snoj M

    更新日期:2012-08-01 00:00:00

  • Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

    abstract::Bladder cancer is one of the leading causes of death in Europe and the United States. About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy. In the setting of metastatic disease, use of cisplatin-based regime...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.09.018

    authors: Morales-Barrera R,Suárez C,de Castro AM,Racca F,Valverde C,Maldonado X,Bastaros JM,Morote J,Carles J

    更新日期:2016-11-01 00:00:00

  • Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.

    abstract::The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells. The most commonly reported result in multi-modalit...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2001.0222

    authors: Gomez GG,Hutchison RB,Kruse CA

    更新日期:2001-12-01 00:00:00

  • Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.

    abstract::Despite the initially high response rate to standard front-line debulking surgery followed by platinum-based chemotherapy, the relapse rate in ovarian cancer is high and many patients will recur within 6 months of completing platinum based treatment. These patients may still require further chemotherapy despite being ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.04.004

    authors: Pinato DJ,Graham J,Gabra H,Sharma R

    更新日期:2013-04-01 00:00:00

  • Fertility preservation in women with borderline ovarian tumours.

    abstract::Borderline ovarian tumours (BOT) may occur in young women and have an excellent survival rate. Therefore, there is the obligation to put emphasis on fertility preservation in affected women. On the other hand, it has also been underlined that the disease should be managed with caution because these tumours can relapse...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.06.010

    authors: Mangili G,Somigliana E,Giorgione V,Martinelli F,Filippi F,Petrella MC,Candiani M,Peccatori F

    更新日期:2016-09-01 00:00:00

  • Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review.

    abstract:BACKGROUND AND AIMS:The use of oral anticancer drugs has increased in modern oncology treatment. The move from intravenous treatments towards oral anticancer drugs has increased the patients' own responsibility to take oral anticancer drugs as being prescribed. High rates of non-adherence to oral anticancer drugs have ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.12.014

    authors: Verbrugghe M,Verhaeghe S,Lauwaert K,Beeckman D,Van Hecke A

    更新日期:2013-10-01 00:00:00

  • Effects of hormonal treatment on lipids in patients with cancer.

    abstract::Patients with malignant disease may need hormonal therapy as primary or adjuvant treatment or for palliation. Oestrogens usually decrease serum levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), increase high density lipoprotein cholesterol (HDL-C) concentration, but induce an elevation ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.09.007

    authors: Filippatos TD,Liberopoulos EN,Pavlidis N,Elisaf MS,Mikhailidis DP

    更新日期:2009-04-01 00:00:00

  • Unraveling galectin-1 as a novel therapeutic target for cancer.

    abstract::Galectins belong to a family of carbohydrate-binding proteins with an affinity for β-galactosides. Galectin-1 is differentially expressed by various normal and pathologic tissues and displays a wide range of biological activities. In oncology, galectin-1 plays a pivotal role in tumor growth and in the multistep proces...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.07.007

    authors: Astorgues-Xerri L,Riveiro ME,Tijeras-Raballand A,Serova M,Neuzillet C,Albert S,Raymond E,Faivre S

    更新日期:2014-03-01 00:00:00

  • Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

    abstract::Patients with solid tumours are at risk of impaired bone health from metastases and cancer therapy-induced bone loss (CTIBL). We review medical management of bone health in patients with solid tumours over the past 30 years, from first-generation bisphosphonates to the receptor activator of nuclear factor κB ligand (R...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.05.003

    authors: von Moos R,Costa L,Gonzalez-Suarez E,Terpos E,Niepel D,Body JJ

    更新日期:2019-06-01 00:00:00

  • Markers of bone turnover in prostate cancer.

    abstract::Prostate cancer is the most common malignancy in elderly men and is often associated with bone metastases. Although bone metastases are osteosclerotic, histological and biochemical studies clearly indicate an increase of both bone formation and bone resorption, providing the rational for using bisphosphonate as a pall...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2000.0213

    authors: Garnero P

    更新日期:2001-06-01 00:00:00

  • Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

    abstract::The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer treatment. Despite the excellent disease control with initial EGFR TKI therapy, acquired resistance is ubiquitous and remains a key chal...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.02.006

    authors: Lim SM,Syn NL,Cho BC,Soo RA

    更新日期:2018-04-01 00:00:00

  • Developments in the systemic treatment of metastatic cervical cancer.

    abstract::Despite the available prevention and early detection strategies, advanced squamous-cell carcinoma of the uterine cervix remains a major concern for public health. Systemic treatment with cisplatin, either in combination with external beam irradiation for locally advanced disease, or as monotherapy for recurrent/metast...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.05.009

    authors: Mountzios G,Soultati A,Pectasides D,Pectasides E,Dimopoulos MA,Papadimitriou CA

    更新日期:2013-08-01 00:00:00

  • Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

    abstract::Antiangiogenic agents (AAs) have reported grater efficacy compared to interferon. Despite these advances, radiological complete response to therapy is rare. We meta-analyzed the incidence of complete response in patients treated with AAs and in controls in main randomized clinical trials for first-line therapy in meta...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2013.09.003

    authors: Iacovelli R,Alesini D,Palazzo A,Trenta P,Santoni M,De Marchis L,Cascinu S,Naso G,Cortesi E

    更新日期:2014-03-01 00:00:00

  • Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

    abstract::Bruton's tyrosine kinase (BTK) is a non-receptor intracellular kinase that belongs to the TEC-family tyrosine kinases together with bone marrow-expressed kinase (BMX), redundant-resting lymphocyte kinase (RLK), and IL-2 inducible T-Cell kinase (ITK). All these proteins play a key role in the intracellular signaling of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.06.001

    authors: Molina-Cerrillo J,Alonso-Gordoa T,Gajate P,Grande E

    更新日期:2017-07-01 00:00:00

  • AR-V7 and prostate cancer: The watershed for treatment selection?

    abstract::The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next-generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic effica...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.12.003

    authors: Ciccarese C,Santoni M,Brunelli M,Buti S,Modena A,Nabissi M,Artibani W,Martignoni G,Montironi R,Tortora G,Massari F

    更新日期:2016-02-01 00:00:00

  • Pediatric sarcomas and related tumors of the head and neck.

    abstract::Sarcomas of the head and neck region are a rare group of tumors in children and present challenges with regard to evaluation and treatment. Rhabdomyosarcomas are the most common sarcomas of the head and neck in children. Presence of metastases and complete surgical resectability continue to be the most relevant clinic...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.04.005

    authors: Huh WW,Fitzgerald N,Mahajan A,Sturgis EM,Beverly Raney R,Anderson PM

    更新日期:2011-10-01 00:00:00

  • Anticancer drugs: estrophilic cisplatin derivatives.

    abstract::Our approach to develop platinum complexes with a selective effect on the hormone-dependent MC by exchanging the two NH3 groups of cisplatin by an 1,2-bis(4-hydroxy-phenyl)ethylenediamine derivative which possesses estrogenic activity, was successful. The most interesting compound of this new platinum complex series, ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(87)90018-1

    authors: Engel J,Schönenberger H,Lux F,Hilgard P

    更新日期:1987-12-01 00:00:00

  • Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

    abstract::Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology commun...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.06.001

    authors: DiSilvestro P,Alvarez Secord A

    更新日期:2018-09-01 00:00:00

  • Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?

    abstract::Despite improvements in the management of patients with early breast cancer, the prognosis for women with locally advanced breast cancer (LABC) remains poor. The potential goals of neoadjuvant treatment for this disease include down-sizing tumours to allow breast conservation as well as the possibility of improving su...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2004.09.008

    authors: Freedman OC,Verma S,Clemons MJ

    更新日期:2005-02-01 00:00:00

  • Adjuvant therapy in colon cancer: current status and future directions.

    abstract::The role of adjuvant chemotherapy in patients with stage III colon cancer is now well established and 5-FU/LV should be the reference regimen to which new drugs are tested against in the adjuvant setting. In stage II colon cancer, because the risk of recurrence is lower, any absolute benefit of chemotherapy is likely ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00047-6

    authors: Chau I,Cunningham D

    更新日期:2002-10-01 00:00:00

  • Metastatic colorectal cancer.

    abstract::Metastatic colorectal cancer remains a public-health issue on a global scale. With development of a new generation of cytotoxic agents, survival has improved for patients with metastatic disease. How to maximize the benefit of chemotherapy with acceptable toxicity remains incompletely answered. Hepatic resection can p...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.07.005

    authors: Saletti P,Cavalli F

    更新日期:2006-11-01 00:00:00

  • Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.

    abstract:BACKGROUND:Surgery is the only curative treatment for primary cutaneous melanoma, therefore it is important to determine excision margins that minimise risk of local recurrence, distant recurrence and death. METHODS:MEDLINE, EMBASE and Cochrane CENTRAL were searched from 2009 to 2015. Inclusion criteria were: populati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2015.10.013

    authors: Wheatley K,Wilson JS,Gaunt P,Marsden JR

    更新日期:2016-01-01 00:00:00

  • Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.

    abstract::Prostate cancer is the most common cancer in men. Overall survival is considered the best endpoint for clinical trials, but it is difficult to use in phase-2 studies. Although the reduction of PSA after cytotoxic chemotherapy has been identified as a valid surrogate for overall survival, it has not proven reliable for...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.03.008

    authors: Colloca G

    更新日期:2012-12-01 00:00:00

  • The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies.

    abstract::Despite recent progress in the diagnostic and therapeutic approaches to the management of women with breast cancer, at least one third of these women will ultimately die from their disease. This resulted in a new focus on breast cancer prevention, especially for the woman designed as "high-risk". The continuing challe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00107-x

    authors: Sakorafas GH

    更新日期:2003-04-01 00:00:00

  • The role of bone markers in metastatic bone disease.

    abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(06)80001-0

    authors: Coleman RE

    更新日期:2006-01-01 00:00:00

  • RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

    abstract::Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene express...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.08.004

    authors: Barata P,Sood AK,Hong DS

    更新日期:2016-11-01 00:00:00

  • Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy.

    abstract::Vinorelbine is a semi-synthetic vinca alkaloid that has been shown active in many tumour types and is currently registered for the treatment of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC). This agent has a generally favourable safety profile, and may be suitable for use in special populations s...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.12.008

    authors: Mano M

    更新日期:2006-04-01 00:00:00

  • Health promotion and psychological interventions for adolescent and young adult cancer survivors: A systematic literature review.

    abstract:BACKGROUND:The effects of cancer and treatment have severe and long lasting negative impacts on quality of life. Adolescents and Young Adults (AYA) have high survival rates but may not reach their full life potential because of these consequences. This review aims to identify, appraise and synthesise the effects of hea...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.02.011

    authors: Bradford NK,Chan RJ

    更新日期:2017-04-01 00:00:00

  • Langerhans cell histiocytosis: Current concepts and treatments.

    abstract::Langerhans cell histiocytosis (LCH) is a rare proliferative disorder of cells with the phenotype of activated Langerhans cells. The diagnosis of LCH is often delayed or missed. Many questions about LCH remain to be answered, including whether it is caused by a malignancy or by immune dysregulation. Data from the early...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.02.012

    authors: Abla O,Egeler RM,Weitzman S

    更新日期:2010-06-01 00:00:00

  • Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

    abstract::Aberrant activation of HER2 through overexpression has been shown to play an important role in some breast cancers. Therapies against this receptor including the monoclonal antibody, trastuzumab, or the small tyrosine kinase inhibitor, lapatinib have shown to improve the prognosis of such patients. Despite overexpress...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.08.001

    authors: Ocaña A,Amir E

    更新日期:2009-12-01 00:00:00